Korro Bio, Inc. (KRRO) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Korro Bio, Inc. for the period ended June 30, 2026. Korro Bio is a biopharmaceutical company developing genetic medicines using its proprietary RNA-editing platform (OPERA). The company is currently pre-commercial, with no approved products, and relies on equity financing and collaboration revenue to fund operations. As of August 5, 2026, there were 14,725,646 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $4.0 million |
| Net Loss | $(18.9) million | $(38.5) million | $(49.2) million |
| Operating Expenses | $20.1 million | $40.5 million | $56.2 million |
| Cash & Marketable Securities | $137.9 million (as of June 30, 2026) | ||
| Accumulated Deficit | $422.4 million (as of June 30, 2026) | ||
| Cash Flow from Operations | $(33.1) million (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped to zero for the six months ended June 30, 2026, compared to $4.0 million in the prior year period. This is due to a 12-month pause in the research collaboration with Novo Nordisk effective November 2025.
- Expense Reduction: Total operating expenses decreased by approximately 28% year-over-year (from $56.2 million to $40.5 million). This reduction is primarily attributed to workforce reductions implemented in May and November 2025 and the termination of the Phase 1/2a REWRITE clinical trial for KRRO-110.
- Capital Raise: In March 2026, the company completed a private placement (PIPE) raising approximately $85.0 million in gross proceeds. Additionally, $5.1 million was raised via an At-The-Market (ATM) offering in January 2026.
- Asset Impairment: While the impairment charge of $30.9 million related to long-lived assets occurred in Q4 2025, its impact on depreciation expenses contributed to lower facility costs in the current period.
Outlook, Risks, and Management Commentary
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($137.9 million) to fund operations into the second half of 2028.
- Pipeline Updates:
- KRRO-121: Lead candidate for hyperammonemia (UCD/HE). Received EMA orphan drug designation in August 2026. First-in-human trial expected to commence in H2 2026.
- KRRO-111: New development candidate for Alpha-1 Antitrypsin Deficiency (AATD) using GalNAc-conjugated delivery, replacing the terminated KRRO-110 program. Preclinical data showed significant reduction of pathogenic aggregates.
- Key Risks:
- Novo Nordisk Pause: The 12-month hold on the collaboration eliminates a key revenue stream and delays potential milestones.
- Clinical Uncertainty: The company has not yet successfully completed a clinical trial. The failure of KRRO-110 highlights the risk of the RNA editing platform and delivery mechanisms.
- Funding Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to advance clinical programs.
Investor Verification Checklist
- Verify the specific terms and potential for extension of the 12-month pause with Novo Nordisk.
- Confirm the timeline and regulatory filing status for the KRRO-121 first-in-human trial.
- Review the detailed preclinical data for KRRO-111 to assess the viability of the GalNAc-conjugated delivery switch.
- Monitor the burn rate relative to the $137.9 million cash balance to validate the "second half of 2028" runway estimate.
- Assess the impact of the recent workforce reductions on the company's ability to execute its clinical development plans.